Metformin improves skeletal muscle microvascular insulin resistance in metabolic syndrome
Linda A. Jahn, LEE HARTLINE, Zhenqi Liu, Eugene J. Barrett
Abstract
Metformin, a first-line treatment for type 2 diabetes, is often used in patients with insulin resistance and metabolic syndrome. Here, we provide the first evidence for metformin improving muscle microvascular insulin sensitivity in insulin-resistant humans. Simultaneously, metformin improved muscle glucose disposal, supporting a close relationship between insulin's microvascular and its metabolic actions in muscle. Whether enhanced microvascular insulin sensitivity contributes to metformin's ability to decrease microvascular complications in diabetes remains to be resolved.
Topics & Concepts
MetforminInsulin resistanceInternal medicineMedicineInsulinMetabolic syndromeSkeletal muscleEndocrinologyType 2 diabetesDiabetes mellitusGlucose uptakeInsulin sensitivityMetabolism, Diabetes, and CancerAdipose Tissue and MetabolismMuscle metabolism and nutrition